Reducing dissemination of carbapenem-resistant Klebsiella pneumoniae

Besides being resistant to several β-lactams, carbapenem-resistant Klebsiella pneumoniae (CRKP) are often resistant to other widely used antimicrobials such as fluoroquinolones and cotrimoxazole, and sometimes to aminoglycosides (1,2). Although possibly not the only reason, the increased risk of delayed/suboptimal treatment consequent to the multidrug-resistant phenotype of CRKP is a major contributor to the high mortality of CRKP infections (3-7).